About Us

For over 75 years, Dana-Farber Cancer Institute has demonstrated an equal commitment to research and care that is unique among cancer centers. To learn more about Dana-Farber and our momentum of discovery, please click here.

• Dana-Farber is the only hospital ranked in the top five nationally by U.S. News & World Report in both adult and pediatric cancer care.
• Dana-Farber investigators played a substantial role in developing more than half (51%) of all cancer drugs approved by the FDA from 2018-2022.
• Dana-Farber is a national leader in conducting clinical trials, and currently has more than 1,100 active clinical trials.
• Dana-Farber is one of the largest recipients of grant funding from the National Cancer Institute.
• Dana-Farber has one of the largest hematology/oncology training programs in the country, which has produced more leaders in oncology than any other program in the nation.
• Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center, one of 57 NCI-designated Comprehensive Cancer Centers in the U.S.
• Dana-Farber is a principal teaching affiliate of Harvard Medical School.
• Dana-Farber’s faculty are among the most highly cited researchers in the world. More than 40 researchers were named to the “Highly Cited Researchers list” by the Institute for Scientific Information at Clarivate, demonstrating significant research influence among their peers.
• Benjamin L. Ebert, MD, PhD, was named President and CEO of Dana-Farber in October of 2024, and is the first Dana-Farber-trained oncologist to serve as president and CEO of the Institute.
• Dana-Farber faculty have been awarded two Nobel Prizes. William G. Kaelin Jr., MD, was the recipient of the Nobel Prize in Physiology or Medicine in 2019, along with two other physician-scientists, for their discoveries of how cells sense and adapt to oxygen availability. Baruj Benacerraf, MD, was awarded the Nobel Prize in Physiology in 1980 for his breakthrough genetic findings.